Multimorbidity: Prevalence, Effect on Quality of Life and Daily Functioning, and Variation of This Effect When one Condition Is a Rheumatic Disease

Loza, Estíbaliz; Jover, Juan A.; Rodríguez, L. Rodríguez; Carmona, Loreto

doi:10.1016/j.semarthrit.2008.01.004

Cited by 130 publications

(102 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A large cohort study in Sweden showed that the prevalence of multiple morbidity among older individuals reaches 55% [21]. To overcome this, we excluded European studies where the distribution of chronic conditions was not stratified by age or where double counting due to co-morbidity was not eliminated [22,23], which in some studies resulted in implausible differences between neighbouring countries [24]. Data available from the Global Burden of Disease and Risk Factors (GBD) project which overcomes double counting could not be used either because it does not directly describe the distribution of risk factors relevant to influenza in the general population [25].…”

Section: Methodsmentioning

confidence: 99%

The scientific basis for offering seasonal influenza immunisation to risk groups in Europe

et al. 2008

View full text Add to dashboard Cite

This paper summarises the scientific evidence supporting selection of risk groups that would benefit from annual seasonal influenza immunisation in European Union (EU) countries. Risk groups are defined restrictively as persons in Europe at higher than average risk of adverse outcomes should they be infected with seasonal influenza and for whom use of vaccine is demonstrated to be effective in reducing the risk of those outcomes. Existing evidence indicate that older people and those with chronic disease are at higher risk of severe adverse outcome and that immunisation reduces this risk. There is thus good scientific evidence for routinely offering annual immunisation to all older people (at least those aged 65 years and older), and people with certain groups of chronic medical conditions. We estimated that these two groups account for between 19% and 28% of the population of EU countries. Thus in 2006, an estimated 84 million older people aged 65 years and over and 41 million people younger than 65 years of age with chronic conditions were living in these countries. There is also strong evidence for immunising staff caring for patients belonging to these two risk groups in residential (care home) settings in order to protect the patients. There are as yet no strong data on whether or not immunising other healthcare workers and carers protect patients though immunisation of healthcare workers can be justified on occupational health grounds. At present the scientific evidence for immunising other suggested risk groups, notably children and pregnant women is not strong for Europe though equally there is no evidence against immunising these groups.

show abstract

Section: Methodsmentioning

confidence: 99%

The scientific basis for offering seasonal influenza immunisation to risk groups in Europe

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Уже имеются единичные доказательства того, что наличие РЗ в среде мультиморбидности дает не просто прибавочный (суммационный), а дополнительный (уси-ливающий) эффект, в отличие от неревматологических составляющих мультиморбидность [31].…”

Section: ел насонов и соавтunclassified

“…В контексте лекарственной терапии выделяют «кон-кордантную» -комбинация хронических болезней, име-ющих синергизм в лечении, и дискордантную мультимор-бидность -комбинация хронических болезней, обуслов-ливающих необходимость взаимоисключающих подходов к лечению или возможность антагонистического взаимо-действия лекарственных средств [26].…”

unclassified

Rheumatic diseases and multimorbidity

Nasonov¹,

Гордеев²,

Галушко³

2015

Ter. arkh.

View full text Add to dashboard Cite

“…También se demuestra el efecto negativo adicional de tener una enfermedad reumática, como parte de esta multimorbilidad. 7 Las enfermedades reumáticas desembocan en el pie con formación de hallux valgus, subluxación, luxación o la erosión de las articulaciones metatarsofalángica (MTF), así como, dedo en martillo o en garra del hallux y en los dedos menores. Las alteraciones de retropié y antepié conllevan a limitación en el rango de movilidad de tobillo, un aumento de presiones en antepié e incremento de dolor durante el levantamiento de peso y actividades deportivas.…”

Section: Introductionunclassified

“…El consumo de recursos sanitarios y sociales por estas enfermedades es muy elevado. es la artritis reumatoide 7 . La investigación de esta afección en el pie está muy limitada, aunque poco a poco se van descubriendo nuevas formas de mejorar sus síntomas.…”

Section: Introductionunclassified

Evidencia científica del tratamiento ortopodológico en pie afectado por artritis reumatoide.

Calleja

García

Fernández

2018

Rev. Int. Cienc. Podol.

View full text Add to dashboard Cite

Resumen. Antecedentes: La artritis reumatoide afecta más a mujeres. La prevalencia en nuestro país es de 0.5%. Se debe abordar mediante un equipo multidisciplinar. Los signos característicos en el pie son sinovitis de las articulaciones, entesitis, nódulos reumatoides y vasculitis. Las modalidades de tratamiento conservador son: ortesis, calzado, estiramientos, terapia manual e incluso ejercicios terapéuticos mediante Tai-chi. Objetivos: Valorar la evidencia científica sobre el tratamiento conservador del pie reumático mediante ortesis plantares y calzado terapéutico. Conocer los últimos avances y que opción es la más indicada para tratar esta patología que afecta al pie. Material y métodos: Se ha realizado una revisión bibliográfica de los últimos 15 años en Pubmed. Resultados: Se ha encontrado relación entre el dolor de antepié, subluxación metatarsofalángica y erosión del cartílago articular con el aumento de presión a nivel metatarsal plantar lo que justifica la realización de tratamiento ortopodológico encaminado a reducir la misma. El tratamiento conservador está enfocado a la utilización de ortesis y de zapato terapéutico para mejorar el dolor, la marcha y la funcionalidad. Hay evidencia científica para tratar la metatarsalgia con diferentes tipos de ortesis, que no solo ayudan a mejorar el dolor sino que además reducen el nº de articulaciones inflamadas. La combinación con zapato terapéutico con o sin modificaciones externas produce mejores resultados. Conclusión: Existe escasa evidencia científica sobre el uso de tratamiento ortopodológico para el pie reumático pero se han encontrado algunos artículos que avalan su eficacia, por lo que es imprescindible realizar estudios en este campo. Palabras clave: artritis reumatoide; ortesis plantar; zapato terapéutico; antepié.[en] Evidence of orthopodiatric treatment affected by rheumatoid arthritis on foot Abstract. Background: Rheumatoid arthritis affects more women. The prevalence in our country is 0.5%. It should be approached by a multidisciplinary team. Characteristic foot signs` are synovitis of joints, enthesitis, rheumatoid nodules and vasculitis. The conservative treatment modalities are: orthotics, footwear, stretching, manual therapy and therapeutic exercises even by Tai -chi. Objectives: To evaluate the scientific evidence on the conservative treatment of rheumatoid foot with orthotics and therapeutic footwear. Aware of progress and that is the most suitable option for treating this disease that affects the feet. Material and methods: We carried out a literature review of the past 15 years in Pubmed . Results: We found the relationship between pain forefoot metatarsophalangeal subluxation and erosion of articular cartilage with increasing pressure to plantar metatarsal level which justifies conducting orthosis treatment aimed at reducing it. Conservative treatment is aimed at the use of orthoses and shoe therapy to improve pain, gait and functionality. There is scientific evidence for treating metatarsalgia with different types of orthotics that not ...

show abstract

Multimorbidity: Prevalence, Effect on Quality of Life and Daily Functioning, and Variation of This Effect When one Condition Is a Rheumatic Disease

Cited by 130 publications

References 35 publications

The scientific basis for offering seasonal influenza immunisation to risk groups in Europe

The scientific basis for offering seasonal influenza immunisation to risk groups in Europe

Rheumatic diseases and multimorbidity

Evidencia científica del tratamiento ortopodológico en pie afectado por artritis reumatoide.

Contact Info

Product

Resources

About